Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and PD-1 Antibody for Unresectable Locally Recurrent Rectal Cancer
NCT06767007Phase 2Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in rectal cancer, sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started Jan 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06767007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767007.